Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Antiviral prophylaxis to prevent hepatitis B reactivation in patients receiving anti–CD20-based chemotherapy and with inactive HBV infection: Systematic review and meta-analysis of randomized controlled trials.

Zain Alabdin Ibrahim, Hasan Daher, Saba Daher et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15034

e15034 Background: Patients with history of inactive hepatitis B receiving anti-CD20-based chemotherapy for lymphoma remai...

Interim analysis of CaboMain: A prospective, single-arm phase 2 clinical trial of cabozantinib as maintenance therapy for patients with “ultra-high-risk” pediatric solid tumors.

Nilay Shah, Elizabeth Alva, Matthew Dietz et al. Jun 01, 2026 pp. 10014-10014 10.1200/jco.2026.44.16_suppl.10014

10014 Background: There are patients with pediatric solid tumors, including those with relapsed/refractory disease, with “...

Risk of multiple primary malignancies in mantle cell lymphoma: Insights from a SEER-based study (2000–2021).

Asem Omar, Sohaib Abukharmh, Ahmad Issa Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19051

e19051 Background: With increasing tumor survival rates and advancements in diagnostics, the incidence of multiple primary...

Treatment with brentuximab vedotin in vitro and CAR T-cell function and viability: Implications for combination or sequential therapeutic approaches for lymphoma.

Meghan Zuck, Bryan Grogan, Catalina Sakai et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15014

e15014 Background: Brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, demonstrates potent cytotoxicity a...

Identifying patients at risk for non-receipt of guideline-concordant treatment in pancreatic cancer using electronic health record data and machine learning.

Annabelle Fonseca, Manish Tripathi, Ioannis Liapis et al. Jun 01, 2026 pp. 1576-1576 10.1200/jco.2026.44.16_suppl.1576

1576 Background: Non-receipt of guideline-concordant treatment (GCT) for pancreatic cancer is associated with worse outcom...

Protective factors supporting caregiver well-being in glioblastoma.

Desiree Reinken, Sean Reed Jun 01, 2026 pp. 12095-12095 10.1200/jco.2026.44.16_suppl.12095

12095 Background: Caregiving in glioblastoma (GBM) means dealing with cancer symptoms, plus the neurological decline that...

A US real-world study of second-line outcomes in advanced ovarian cancer by first-line PARP inhibitor maintenance exposure.

Lei Chen, Petar Jelinic, Elizabeth A. Szamreta et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17564

e17564 Background: As PARPi maintenance (MTx) is widely used after first-line (1L) platinum-based therapy for advanced ova...

Metric indicators of lymphedema and their impact on symptoms and quality of life in breast cancer patients: A longitudinal real-world study.

Denisa Piele, Michael Schenker, Puiu Olivian Stovicek et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12713

e12713 Background: Upper-limb lymphedema is a frequent complication of breast cancer, with impact on symptoms and quality...

Intrathecal iPSC-derived natural killer cells combined with the Stupp regimen for newly diagnosed WHO grade 4 glioma: A phase I trial.

Yulun Huang, Xiang Li, Xuetao Li et al. Jun 01, 2026 pp. 2072-2072 10.1200/jco.2026.44.16_suppl.2072

2072 Background: WHO grade 4 glioma has a poor prognosis despite standard Stupp therapy. Induced pluripotent stem cell–der...

AI-assisted prediction of radiation failure patterns and survival after stereotactic radiosurgery for brain metastases: A multicenter study.

Yuming Jiang, Yijun Chen, Christina Cramer et al. Jun 01, 2026 pp. 2023-2023 10.1200/jco.2026.44.16_suppl.2023

2023 Background: Brain metastases occur in approximately 20%–40% of patients with cancer and are associated with substanti...

Adolescent and young adult cancer death burden in the United States from 1990 to 2023.

James Fan Wu, Ruoyi Zhang, Nishwant Swami et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22599

e22599 Background: Reports of increasing adolescent and young adult (AYA) cancer burden in the United States (US) may be i...

Safety and efficacy of perioperative use of tislelizumab in treating clinically node-positive urothelial carcinoma: A prospective clinical study.

Xiao Yang, Qiang Cao, Qiang Lyu Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16615

e16615 Background: Recent studies suggest that the preservation of tumor-draining lymph nodes (TDLN) may enhance the sensi...

Cholangiocarcinoma care across America: A tale of two coasts.

Daniel Cruceta Reynoso, Cesar O. Ortiz, Anu Priyamvadha Ramakrishnan Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16241

e16241 Background: Cholangiocarcinoma (CCA) is an aggressive biliary cancer with a historically poor prognosis and a recen...

Multicenter clinical study of [ <sup>18</sup> F]AlF-HER2-BCH PET/CT as a molecular pathology tool for linear quantification of HER2 expression levels in breast cancer.

Xiaoyi Guo, Xu Liang, Hua Zhu et al. Jun 01, 2026 pp. 3071-3071 10.1200/jco.2026.44.16_suppl.3071

3071 Background: Determining the human epidermal growth factor receptor 2 (HER2) status is essential in metastatic breast...

Assessment of CAR-T clinical trial availability and accessibility in the United States.

Rahul Kumar Thakur, Xiaoyi Zhang, Nikhil Chaudhary et al. Jun 01, 2026 pp. 1558-1558 10.1200/jco.2026.44.16_suppl.1558

1558 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed outcomes in hematologic malignancies and...

Global lung cancer burden attributable to environmental and occupational exposures.

Akshee Batra, Chinmay Jani, Atulya Aman Khosla et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22677

e22677 Background: Lung cancer without tobacco exposure is a growing and preventable source of global morbidity driven by...

Gut microbiome characteristics in patients with hormone receptor–positive (HR+) HER2− breast cancer treated with adjuvant abemaciclib: Biomarker analysis of the TRADE trial.

Ilana Schlam, Emily Anne Green, Xochitl Morgan et al. Jun 01, 2026 pp. 563-563 10.1200/jco.2026.44.16_suppl.563

563 Background: Adjuvant abemaciclib reduces recurrence risk and improves overall survival in patients with high-risk node...

Improving multidisciplinary care in the treatment of muscle-invasive bladder cancer: A quality improvement initiative.

Scott T. Tagawa, Katie S. Murray, Bradley Alexander McGregor et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23315

e23315 Background: The rapidly evolving treatment landscape for bladder cancer has introduced several new therapy classes,...

CheckMate-901: Association of tumor and peripheral biomarker profiles with durable disease control in metastatic urothelial carcinoma treated with nivolumab plus ipilimumab.

Matthew D. Galsky, Guru P. Sonpavde, Michiel S. Van Der Heijden et al. Jun 01, 2026 pp. 4525-4525 10.1200/jco.2026.44.16_suppl.4525

4525 Background: Patients (pts) with untreated, unresectable, or metastatic urothelial carcinoma (mUC) have limited therap...

A machine learning model for predicting recurrence and survival in stage I-III colorectal cancer.

Mariam Manukyan, Tigran Gevorkyan, Aydar Akhmetzyanov et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15518

e15518 Background: While 5-year overall survival for stage I-III colorectal cancer (CRC) is relatively high, the risk of r...

CAPTURE: A phase II trial evaluating alpelisib + fulvestrant vs capecitabine in advanced breast cancer patients with <i>PIK3CA</i> -mutant circulating DNA following CDK4/6 inhibition.

Eileen Geoghegan, Ankit K. Dutta, Samuel M. Niman et al. Jun 01, 2026 pp. 1064-1064 10.1200/jco.2026.44.16_suppl.1064

1064 Background: PIK3CA mutations are a key therapeutic target in ER+ advanced breast cancer (ABC) rea...

Clinical impacts of the 2025 Southern California wildfires among childhood cancer patients and survivors: A pilot study.

Judy Ou, Nancy Daher, Angela Parra Del Riego et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13515

e13515 Background: Climate change-related natural hazards threaten healthcare delivery, and wildfires are one such hazard....

Pulmonary metastasis in chondroblastoma: An institutional cohort and meta-analysis.

Shamus Flatley, Dylan Riley, Mayssa Chehab et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23506

e23506 Background: Chondroblastoma is a benign bone tumor with rare potential for pulmonary metastasis. The true incidence...

Intracranial Rosai–Dorfman disease: Systematic review of published case reports and small series (2000–2025).

Abeer Almusleh, Ayman Khaled, Mohammad Bdair et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14108

e14108 Background: Intracranial Rosai-Dorfman disease (RDD) is a rare histiocytic disorder that often mimics meningioma an...

HER2 expression heterogeneity (IHC/FISH) in breast cancer: A systematic review and meta-analysis of prognostic implications.

Sakshi Kumari, Anirudh Govind, Nabahat Shafi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13023

e13023 Background: Human epidermal growth factor receptor 2 (HER2/ERBB2) is a validated predictive and prognostic biomarke...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page